SLS - CIK 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $107.10M | $44.32M | $25.30M | $28.40M | $21.03M | $9.15M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $111.17M |
| $49.05M |
| $29.45M |
| $31.97M |
| $24.04M |
| $12.30M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M |
| Total assets | $114.18M | $51.55M | $32.30M | $34.96M | $26.50M | $15.12M |
| Accounts payable | $3.63M | $2.31M | $3.34M | $3.76M | $4.55M | $6.33M |
| Total current liabilities | $6.46M | $5.92M | $6.00M | $6.89M | $10.61M | $12.04M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $6.76M | $5.92M | $6.16M | $7.20M | $10.61M | $12.21M |
| Retained earnings | -$283.39M | -$267.33M | -$260.54M | -$253.94M | -$241.39M | -$234.28M |
| Total equity | $107.41M | $45.63M | $26.15M | $27.76M | $15.89M | $2.91M |